86
Participants
Start Date
October 25, 2025
Primary Completion Date
December 30, 2028
Study Completion Date
July 30, 2029
ABSK043 in combination with Glecirasib
"Dose escalation cohort( Part A) ABSK043 150 mg BID in combination with Glecirasib 200 mg QD will be selected as the starting dose.~Based on the accumulated safety data and PK profile, the Safety Review Committee (SRC), composed of the investigator and the sponsor, may discuss and agree to allow exploration of other possible doses.~Dose confirmation cohort (Part B) and Expansion cohort Patients in dose confirmation cohort and expansion cohort will receive the recommended dose in dose escalation cohort and be evaluated for safety and preliminary anti-tumor activity.~All patients will continue to receive combination therapy every 21 days until disease progression, death, loss to follow-up, withdrawal of consent, intolerable toxicity, investigator decision to discontinue treatment, or end of the study."
The First Affiliated Hospital of Anhui Medical University, Hefei
Beijing Cancer Hospital, Beijing
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
Fujian Cancer Hospital, Fuzhou
The First Affiliated Hospital of Sun Yat-sen University, Guangzhou
Guangxi Medical University Cancer Hospital & Guangxi Cancer Institude, Nanning
Harbin Medical University Cancer Hospital, Harbin
Henan Cancer Hospital, Zhengzhou
Tongji Hospital Tongji Medical College of Hust, Wuhan
Hunan Cancer Hospitial, Changsha
Zhongda Hospital Southeast University, Nanjing
The First Hospital of China Medical University, Shenyang
Central Hospital Affiliated to Shangdong First Medical University, Jinan
Shanghai Chest Hospital, Shanghai
Shanghai Pulmonary Hospital, Shanghai
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
West China Hospital Sichuan University, Chengdu
Lead Sponsor
Abbisko Therapeutics Co, Ltd
INDUSTRY